1st IBDHorizons Gulf Coast Symposium
In collaboration with GI Alliance, IBDHorizons Presents its First Gulf Coast Symposium in New Orleans, LA, with Co-Chairs Dr. Casey Chapman and Dr. Tim Ritter.
IBDHorizons provides free IBD conferences open to all those who treat IBD, desire to treat IBD, and who face IBD.
At our 1st Annual Gulf Coast IBD Conference, you will learn from and engage in discourse about the latest in Inflammatory Bowel Disease (IBD) from world-renowned faculty, on Saturday, October 15, 2022.
During the IBDHorizons Gulf Coast Symposium, you’ll be provided with a smooth experience including catered meals, thoughtful breaks throughout the day’s events, and a personal tablet to engage with the presentations. We dedicate more time than most other IBD education conferences to our open panel discussions and real-world case studies to be examined alongside the faculty.
Our IBD conference will be hosted at Omni Royal Orleans, 621 St Louis St, New Orleans, LA. See below table for the schedule of the day’s breakdown list of topics and faculty.
CME/CE/CPE
This IBDHorizons event will be accredited for up to 6 CME, CE, and CPE credit hours for attendees.
Cost
Registration is required to plan accordingly, but registration for IBDHorizons New Orleans is complimentary to attendees!
Lodging
If you are not local to Omni Royal Orleans Hotel, accommodations are available at a discounted rate, limited availability. The booking link is available after registering or by contacting us.
Parking
Limited valet parking is available on-site at the Omni Royal Orleans Hotel,’s garage, located on Chartres Street. The hotel is located on the corner of St. Louis and Chartres Street. If utilizing valet parking, please bring the ticket to the event registration desk to receive a stamp for a discounted event parking rate of $15 (cash only).
If the lot is full, self-parking will need to be found nearby. The lot across the street (535 Chartres St) offers self-parking. More info for this lot can be found at https://www.premiumparking.com/P149
Join us for this amazing IBD conference opportunity to engage with key/known/notable leaders in the field of Inflammatory Bowel Disease (IBD).
Virtual Attendance
We strive to be inclusive to all of the IBD community for our IBDHorizons conferences. While we prefer to have attendees in person, we understand the need for virtual attendance to our sessions. Please register at this event link and a secured link will be emailed to you on October 15th.
-
Accreditation:
1st IBDHorizons Gulf Coast Symposium
Course Information
1 day - multiplatform meeting for in-person & virtual participation covering Louisiana and the surrounding region with an estimated 200 attendees. An exclusively virtual conference platform will be offered if an in-person meeting cannot be safely conducted.Intended Audience
This activity was developed for healthcare providers caring for IBD patients, including gastroenterologists, surgeons, gastroenterology nurses, advanced nurse practitioners, physician assistants, and pharmacists.Learning Objectives
At the conclusion of this learning activity, participants will do the following:- Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
- Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
- Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
- Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
- Describe the clinical presentation of Crohn’s disease patients with strictures and discuss the best management for strictures including surgical intervention, endoscopic management and medical treatments.
- Recognize the postoperative clinical course for IBD patients who undergo surgery and review the medical and surgical challenges and their optimal management.
- Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention.
- Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.
Accreditation and Certification
In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Annenberg Center designates this live activity for a maximum of 6.0 American Nurses Credentialing Center (ANCC) contact hour, which includes 1.50 hours of pharmacology credit.Pharmacists
This activity is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.
Disclosure Statement
All individuals in control of the content of continuing education activities provided by the Annenberg Center are required to disclose to the audience all relevant financial relationships related to the content of the activity. Full disclosure of all relevant financial relationships will be made in writing to the audience prior to the activity.The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
All staff at the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons have no relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
This activity is supported by educational grants from AbbVie, Bristol Myers Squibb, Ferring Pharmaceuticals, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Takeda Pharmaceuticals USA, Inc.
IBDHorizons Privacy Policy
https://ibdhorizons.org/privacy-policy/Annenberg Center for Health Sciences Privacy Policy
Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php - Disclosure Statements: https://ibdhorizons.org/wp-content/uploads/2022/10/Disclosure-Statements_Gulf-Coast.pdf
Hourly Schedule
Morning Session
- 8:00 - 8:15
- Welcome & Introduction
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- 8:15 - 9:00
- Women's Health in IBD and The Parenthood Project
-
Speakers:
Rajeev Jain-- MD
- 9:00 - 9:45
- Update on Positioning Therapies and Comparative Efficacy
- 9:45 - 10:15
- Break
- 10:15 - 11:00
- Advances in J-Pouch Management
-
Speakers:
Feza Remzi-- MD
- 11:00 - 11:45
- State of the Art in Disease and Therapeutic Monitoring
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- 11:45 - 12:30
- Lunch
Afternoon Session
- 12:30 - 1:00
- Fibrostenotic Crohn's Disease: Present and Future
-
Speakers:
Tina Ha-- MD
- 1:00 - 1:45
- Postoperative Disease Management in IBD
-
Speakers:
Gary Lichtenstein-- MD
- 1:45 - 2:30
- Cancer Risk and Dysplasia Screening in IBD
-
Speakers:
Bincy Abraham-- MD
- 2:30 - 3:15
- Novel Pathways and Upcoming New IBD Therapies
-
Speakers:
Brian Feagan-- MD-- MSc
- 3:15 - 3:30
- Closing
Date
Time
Location
Speakers
-
Anita Afzali, MD, MPH, MHCMProfessor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
-
Bincy Abraham, MDDirector, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital
Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital.
Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation (CCF) at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology.
Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCF Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology (ACG), a member of American Gastroenterology Association (AGA), and Crohn’s and Colitis Foundation.
-
Brian Feagan, MD, MScProfessor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Inflammatory Bowel Diseases (IBD), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in IBD. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology (ACG), the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored numerous articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
-
Casey Chapman, MDChief Medical Officer, GI Alliance
Dr. Casey Chapman is the Chief Medical Officer for GI Alliance. He is an actively practicing gastroenterologist in Baton Rouge, LA, focusing on Inflammatory Bowel Disease (IBD).
Dr. Chapman earned his medical degree from Louisiana State University School of Medicine. He completed his residency and fellowship at LSU Health Science Center.
-
Feza Remzi, MDVice President and Colorectal Surgeon at Northwell Health Center for Advanced IBD Care, New York
Dr. Feza Remzi is the Vice President and a colorectal surgeon at the Center for Advanced IBD Care at Northwell Health in New York.
He is a national and international expert in colorectal surgery, specializing in the surgical management of inflammatory bowel disease (IBD). He performs pelvic pouch surgery, complex abdominopelvic re-operative surgery, and sphincter-saving surgery for rectal cancer, utilizing minimally invasive techniques to manage colorectal conditions.
Dr. Remzi resides in New York with his wife and son. They enjoy traveling and spending time together as a family.
Dr. Remzi is an Honorary IBDHorizons Board member.
@FezaRemziMD
-
Gary Lichtenstein, MDDirector, Inflammatory Bowel Disease Center, Professor of Medicine, University of Pennsylvania
Gary R. Lichtenstein, MD, FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania.
Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. His current research interests encompass investigational therapies for the treatment of IBD. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of IBD.
-
Ghassan Wahbeh, MDDirector of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations.
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine and Director of Clinical Gastroenterology Operations. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with IBD, including advanced therapeutics and perioperative IBD management. He leads the Intestinal Ultrasound (IUS) Program at Seattle Children’s.
Dr. Wahbeh’s research interests include novel therapeutics for pediatric IBD, advanced disease monitoring towards mucosal healing, clinical standard work in managing severe ulcerative colitis and complicated Crohn’s disease including fistulizing and stricturing phenotypes, and navigating IBD surgical options. He is actively involved in translational IBD research at Seattle Children’s Hospital.
Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty, and advanced IBD specialty training.
He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohn’s & Colitis Foundation service award. Dr. Wahbeh enjoys playing soccer, skiing, and paddle-boarding with his wife and kids.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
-
Rajeev Jain, MDBoard Certified Gastroenterologist, Chief of Gastroenterology, Texas Digestive Disease Consultants
Dr. Rajeev Jain is a gastroenterologist whose specialty blends the needs for diagnostic reasoning with procedural interventions across a broad variety of symptoms and disorders.
I am interested in colon cancer screenings, heartburn, Barrett’s esophagus, and inflammatory bowel disease (IBD).
Studied at:
Undergrad: University of Texas at Austin,
Medical School: Baylor College of Medicine,
Residency in Internal Medicine and Fellowship in Gastroenterology: University of Texas Southwestern Medical School.Certifications Held:
Board Certified in Gastroenterology. I am a Fellow of the American College of Physicians, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy.Dr. Jain has been named annually to D Magazine “Best Doctors” in Dallas since 2001. In 2002, he was appointed as Chief of Gastroenterology at Texas Health Presbyterian Hospital. Since 2006, he has been annually named a Texas Monthly Super Doctor. He received the Presbyterian Hospital House Staff Annual Robert L. North, M.D. Teaching Award for 2002-2003. In December 2012, Dr. Jain was presented the Outstanding Contribution in the Field of Medicine award by the Greater Dallas Indo-American Chamber of Commerce. He served on the Texas Society for Gastrointestinal Endoscopy (TSGE) as a Councilor from 2013-2015. I serve on the Governing Board of the American Gastroenterological Association (AGA) as Clinical Practice Councillor from 2015-2017, as well as on the Board of Directors for the American Board of Internal Medicine (ABIM) from 2016-2018.
-
Scott D. Lee, MDAssociate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
Dr. Scott D. Lee is an Associate Professor of Medicine with expertise in inflammatory bowel diseases. Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCF), American Gastroenterology Association (AGA), American College of Gastroenterology (ACG), and American Society of Gastrointestinal Endoscopy (ASGE). He is a past chair of Northwest CCF Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
-
Tim Ritter, MD, FASGESenior Medical Director of the Department of Research and Education at GI Alliance
Dr. Timothy Ritter is Senior Medical Director of the Department of Research and Education at GI Alliance. His interest within GI is Inflammatory Bowel Diseases (IBD) and Clinical Trials.
He is a practicing gastroenterologist in Southlake, Texas and an Assistant Professor of Medicine at TCU School of Medicine.
Dr. Ritter earned his medical degree from the University of Texas Southwestern, where he also completed his residency and fellowship. He was awarded a Regional Top Doctor in 2014 by Castle Connolly and is a professional member of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the Texas Society for Gastroenterology & Endoscopy (TSGE), and the American Society for Gastrointestinal Endoscopy (ASGE).
-
Tina Ha, MDDirector, Inflammatory Bowel Diseases Section, Mayo Clinic Arizona
Dr. Tina Ha is a gastroenterologist at the Mayo Clinic in Scottsdale, Arizona. She is the Director of the Inflammatory Bowel Diseases Section.
Dr. Ha earned her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She completed an internal medicine residency at Washington University at St. Louis School of Medicine as well as a fellowship in gastroenterology. She continued to a fellowship in inflammatory bowel disease (IBD) at the Icahn School of Medicine at Mount Sinai.
She likes to spend her free time with friends and family, and exploring the outdoors with her golden retriever Sebastian – who does not enjoy walking or retrieving.
@tinahamd
Hourly Schedule
Morning Session
- 8:00 - 8:15
- Welcome & Introduction
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- 8:15 - 9:00
- Women's Health in IBD and The Parenthood Project
-
Speakers:
Rajeev Jain-- MD
- 9:00 - 9:45
- Update on Positioning Therapies and Comparative Efficacy
- 9:45 - 10:15
- Break
- 10:15 - 11:00
- Advances in J-Pouch Management
-
Speakers:
Feza Remzi-- MD
- 11:00 - 11:45
- State of the Art in Disease and Therapeutic Monitoring
-
Speakers:
Anita Afzali-- MD-- MPH-- MHCM
- 11:45 - 12:30
- Lunch
Afternoon Session
- 12:30 - 1:00
- Fibrostenotic Crohn's Disease: Present and Future
-
Speakers:
Tina Ha-- MD
- 1:00 - 1:45
- Postoperative Disease Management in IBD
-
Speakers:
Gary Lichtenstein-- MD
- 1:45 - 2:30
- Cancer Risk and Dysplasia Screening in IBD
-
Speakers:
Bincy Abraham-- MD
- 2:30 - 3:15
- Novel Pathways and Upcoming New IBD Therapies
-
Speakers:
Brian Feagan-- MD-- MSc
- 3:15 - 3:30
- Closing
-
Accreditation:
1st IBDHorizons Gulf Coast Symposium
Course Information
1 day - multiplatform meeting for in-person & virtual participation covering Louisiana and the surrounding region with an estimated 200 attendees. An exclusively virtual conference platform will be offered if an in-person meeting cannot be safely conducted.Intended Audience
This activity was developed for healthcare providers caring for IBD patients, including gastroenterologists, surgeons, gastroenterology nurses, advanced nurse practitioners, physician assistants, and pharmacists.Learning Objectives
At the conclusion of this learning activity, participants will do the following:- Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
- Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
- Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
- Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
- Describe the clinical presentation of Crohn’s disease patients with strictures and discuss the best management for strictures including surgical intervention, endoscopic management and medical treatments.
- Recognize the postoperative clinical course for IBD patients who undergo surgery and review the medical and surgical challenges and their optimal management.
- Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention.
- Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.
Accreditation and Certification
In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
The Annenberg Center designates this live activity for a maximum of 6.0 American Nurses Credentialing Center (ANCC) contact hour, which includes 1.50 hours of pharmacology credit.Pharmacists
This activity is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.
Disclosure Statement
All individuals in control of the content of continuing education activities provided by the Annenberg Center are required to disclose to the audience all relevant financial relationships related to the content of the activity. Full disclosure of all relevant financial relationships will be made in writing to the audience prior to the activity.The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
All staff at the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons have no relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
This activity is supported by educational grants from AbbVie, Bristol Myers Squibb, Ferring Pharmaceuticals, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Takeda Pharmaceuticals USA, Inc.
IBDHorizons Privacy Policy
https://ibdhorizons.org/privacy-policy/Annenberg Center for Health Sciences Privacy Policy
Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php - Disclosure Statements: https://ibdhorizons.org/wp-content/uploads/2022/10/Disclosure-Statements_Gulf-Coast.pdf